Crossmark

Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma

Published Online: 2016-10-31

Published Print: 2017-02

Authors

Piao, W

Chau, D https://orcid.org/0000-0003-1205-4156
Yue, L M

Kwong, Y-L

Tse, E
License Information

Text and Data Mining valid from 2016-10-31

Version of Record valid from 2016-10-31
More Information

Article History

First Online: 31 October 2016

Competing interests

: The University of Hong Kong holds the patent for the use of oral formulation of arsenic trioxide in USA and Japan. DC, YLK and ET are employees of the University of Hong Kong.

Document is current